gene-modified cells, which may become instrumental for the clinical application of next-generation bispecific immunomodulatory antibodies.
No takes yet. Share an insight, caveat, or question.
Blanco et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: